Is 6-Shogaol an Effective Phytochemical for Patients With Lower-risk Myelodysplastic Syndrome? A Narrative Review

Soo Liang Ooi, Ron Campbell, Sok Cheon Pak, Terry Golombick, Arumugam Manoharan, Raj Ramakrishna, Vladimir Badmaev, Janet Schloss

Research output: Contribution to journalReview articlepeer-review

Abstract

Myelodysplastic syndrome (MDS) evolves due to genomic instability, dysregulated signaling pathways, and overproduction of inflammatory markers. Reactive oxygen species contribute to the inflammatory response, which causes gene damage, cellular remodeling, and fibrosis. MDS can be a debilitating condition, and management options in patients with MDS aim to improve cytopenias, delay disease progression, and enhance quality of life. High serum ferritin levels, a source of iron for reactive oxygen species production, correlate with a higher risk of progression to acute myeloid leukemia, and iron overload is compounded by blood transfusions given to improve anemia. 6-shogaol is a natural phenolic compound formed when ginger is exposed to heat and/or acidic conditions, and it has been shown to possess anti-tumor activity against leukemia cell lines and antioxidant effects. This narrative review assessed the potential benefits of this phytochemical in lower-risk MDS patients through examining the current evidence on the pharmacological and therapeutic properties of ginger and 6-shogaol.

Original languageEnglish
Pages (from-to)1-12
Number of pages12
JournalIntegrative Cancer Therapies
Volume20
DOIs
Publication statusPublished - Dec 2021

Fingerprint

Dive into the research topics of 'Is 6-Shogaol an Effective Phytochemical for Patients With Lower-risk Myelodysplastic Syndrome? A Narrative Review'. Together they form a unique fingerprint.

Cite this